Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VACCINEX, INC.VCNX · Entity 9673 | SVP, Development | March 31, 2023 | April 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VACCINEX, INC.
Report date March 31, 2023 · Filed April 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.40 · Expires 2033-03-30 | Direct | 20,000 |
Reported balance
After 2023-03-31 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-03-31 · Grant · Acquired 20,000 · Balance 20,000 F5: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 31, 2023 grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.10 · Expires 2025-12-22 | Direct | 23,150 |
Reported balance
Holding disclosure · report date 2023-03-31 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 23,150 F1: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.10 · Expires 2025-12-23 | Direct | 3,062 |
Reported balance
Holding disclosure · report date 2023-03-31 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 3,062 F1: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.90 · Expires 2029-03-14 | Direct | 3,000 |
Reported balance
Holding disclosure · report date 2023-03-31 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 3,000 F1: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.07 · Expires 2030-02-24 | Direct | 4,000 |
Reported balance
Holding disclosure · report date 2023-03-31 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 4,000 F2: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the February 25, 2020 grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.93 · Expires 2031-04-02 | Direct | 8,000 |
Reported balance
Holding disclosure · report date 2023-03-31 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 8,000 F3: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the April 2, 2021 grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.29 · Expires 2032-04-01 | Direct | 16,000 |
Reported balance
Holding disclosure · report date 2023-03-31 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 16,000 F4: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the April 1, 2022 grant date. |
| Common StockSEC Table I · non-derivative | Direct | 2,258 |
Reported balance
Holding disclosure · report date 2023-03-31 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,258 |
| Common StockSEC Table I · non-derivative | IndirectBy John Leonard Consulting, LLC | 1,014 |
Reported balance
Holding disclosure · report date 2023-03-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,014 |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable in full as of the date of this report.
F2: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the February 25, 2020 grant date.
F3: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the April 2, 2021 grant date.
F4: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the April 1, 2022 grant date.
F5: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 31, 2023 grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2023 Filed Apr 3, 2023 16:35 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001062993-23-008326 · form4.xml · derivative · entry 9 Leonard John E. · CIK 0001747997 · SVP, Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-03-30 F5 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 31, 2023 grant date. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 16:36 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001062993-22-009450 · form4.xml · derivative · entry 8 Leonard John E. · CIK 0001747997 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2032-04-01 F5 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the April 1, 2022 grant date. Read SEC document |
| April 02, 2021 Filed Apr 2, 2021 16:26 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0000891839-21-000099 · edgar.xml · derivative · entry 7 Leonard John E. · CIK 0001747997 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2031-04-02 F4 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the April 2, 2021 grant date. Read SEC document |
| July 27, 2020 Filed Jul 27, 2020 16:16 UTC | VACCINEX, INC. VCNX · Entity 9673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0000891839-20-000213 · edgar.xml · derivative · entry 5 Leonard John E. · CIK 0001747997 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 1,000 shares Expires 2029-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 15, 2019 grant date. Read SEC document |
| July 27, 2020 Filed Jul 27, 2020 16:16 UTC | VACCINEX, INC. VCNX · Entity 9673 | Exercise / conversionCommon Stock | 1,000 | $3.90 | $3,900.00 |
DisclosureSEC source: 0000891839-20-000213 · edgar.xml · nonDerivative · entry 1 Leonard John E. · CIK 0001747997 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2020 Filed Jul 28, 2020 16:19 UTC Amendment | VACCINEX, INC. VCNX · Entity 9673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0000891839-20-000214 · edgar.xml · derivative · entry 6 Leonard John E. · CIK 0001747997 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 1,000 shares Expires 2029-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 15, 2019 grant date. Read SEC document |
| July 27, 2020 Filed Jul 28, 2020 16:19 UTC Amendment | VACCINEX, INC. VCNX · Entity 9673 | Exercise / conversionCommon Stock | 1,000 | $3.90 | $3,900.00 |
DisclosureSEC source: 0000891839-20-000214 · edgar.xml · nonDerivative · entry 2 Leonard John E. · CIK 0001747997 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 24, 2020 Filed Jul 28, 2020 16:19 UTC Amendment | VACCINEX, INC. VCNX · Entity 9673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,258 | $0.00 Strike: $7.10 | $0.00 |
DisclosureSEC source: 0000891839-20-000214 · edgar.xml · derivative · entry 4 Leonard John E. · CIK 0001747997 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,150 Underlying: Common Stock · 1,258 shares Expires 2025-12-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Exercisable in full as of the date of this report. Read SEC document |
| July 24, 2020 Filed Jul 28, 2020 16:19 UTC Amendment | VACCINEX, INC. VCNX · Entity 9673 | Exercise / conversionCommon Stock | 1,258 | $7.10 | $8,931.80 |
DisclosureSEC source: 0000891839-20-000214 · edgar.xml · nonDerivative · entry 1 Leonard John E. · CIK 0001747997 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 14, 2020 Filed Sep 3, 2020 16:16 UTC Amendment | VACCINEX, INC. VCNX · Entity 9673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0000891839-20-000255 · edgar.xml · derivative · entry 2 Leonard John E. · CIK 0001747997 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 1,000 shares Expires 2029-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 15, 2019 grant date. Read SEC document |
| July 14, 2020 Filed Sep 3, 2020 16:16 UTC Amendment | VACCINEX, INC. VCNX · Entity 9673 | Exercise / conversionCommon Stock | 1,000 | $3.90 | $3,900.00 |
DisclosureSEC source: 0000891839-20-000255 · edgar.xml · nonDerivative · entry 1 Leonard John E. · CIK 0001747997 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 16:25 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0000891839-20-000053 · edgar.xml · derivative · entry 5 Leonard John E. · CIK 0001747997 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2030-02-24 F3 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the February 25, 2020 grant date. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 16:48 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0000891839-19-000048 · edgar.xml · derivative · entry 4 Leonard John E. · CIK 0001747997 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2029-03-14 F3 · derivative.exercise_date: This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 15, 2019 grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.